Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Sangamo BioSciences Inc. ($SGMO) stock snapped its negative streak as it jumped to $3.35 in its Friday trading session. The stock eventually closed at $3.20, 18.52% higher. The company presented preclinical and manufacturing data that support SB-525, its gene therapy program for hemophilia A, at the 58th Annual Meeting of the American Society of Hematology (ASH) held in San Diego, CA, from December 3-6, 2016.
Sangamo reported that the data showed the company’s ability to perform beyond its ZFP platform. It also demonstrated its R&D and technical operations teams’ ability to rapidly develop a program from research data.

Emergent BioSolutions ($EBS) reported inking a new deal with the US Centers for Disease Control and Prevention (CDC) for supplying nearly 29.4 million doses of anthrax vaccine BioThrax to the Strategic National Stockpile (SNS) through September 2021. The deal is expected to be worth about $911 million.
The company also updated its guidance for FY 2016. Emergent BioSolutions now expects its revenue to be in the range of $485 million and $505 million with Aptevo, while without Aptevo, its revenue is likely to fall between $465 million and $485 million. Similarly, its income is expected to be in the range of $35 million to $45 million and $50 million to $60 million with and without Aptevo respectively. The company had spun off from Aptevo Therapeutics in August this year.


• St. Jude Medical ($STJ) reported that its Proclaim Elite Spinal Cord Stimulation (SCS) System has received CE Mark (with conditions) for use is patients undergoing full-body magnetic resonance imaging (MRI). Earlier the system was approved only for MRIs of the head and extremities.
• Boston Scientific ($BSX) filed a patent infringement suit against Nevro ($NVRO) in a Delaware district court. The company accused Nevro of infringing patents covering technology related to stimulation leads, batteries and telemetry units used in Nevro's Senza system.

• Synergy Pharmaceuticals' ($SGYP) announced that the results for the first of two Phase 3 clinical trials for plecanatide for the treatment of adult patients with irritable bowel syndrome with constipation (IBS-C). The company reported that the treatment met its primary endpoint of overall response rate at week 12.
• Biogen ($BIIB) announced the news of its Alzheimer's disease candidate aducanumab showing positive data from a Phase 1 study. The company presented the data at the CTAD meeting in San Diego.


• Eli Lilly ($LLY) signed an agreement with AstraZeneca ($AZN) to co-develop MEDI1814, an antibody selective for amyloid beta 42 currently in Phase 1 development. The new collaboration rests upon the companies' existing alliance related to BACE inhibitor AZD3293, in Phase 3 development.


• The Cooper Companies ($COO) reported its fourth quarter EPS at $2.28, beating the consensus estimates by $0.03. The company reported its revenue at $518.65 million, up 13.9% on year over year basis. The figure surpassed the estimates by $0.03.

• Mednax ($MD) receives initial rating of Neutral from Goldman Sachs. The price target for the stock is fixed at $66.
• Horizon Pharma ($HZNP) stock received rating downgrade from Mizuho Securities. The stock’s new rating is Neutral, down from Buy and its price target is fixed at $14, down from earlier $30.

Gainers (% price change) Last Trade Change Mkt Cap
Emergent Biosolutions Inc
32.37 +5.15 (18.92%) 1.35B
Sangamo Biosciences, Inc.
3.20 +0.50 (18.52%) 206.84M
Derma Sciences Inc
4.85 +0.35 (7.78%) 135.60M
Spectrum Pharmaceuticals
4.44 +0.28 (6.73%) 359.41M
The Medicines Company
34.85 +2.03 (6.19%) 2.43B
Losers (% price change)
IRIDEX Corporation
14.05 -1.46 (-9.41%) 148.42M
Synergy Pharmaceuticals
5.22 -0.32 (-5.78%) 949.64M
GTx, Inc.
6.51 -0.39 (-5.65%) 109.01M
Enzo Biochem, Inc.
7.06 -0.42 (-5.61%) 335.71M
Curis, Inc.
2.91 -0.17 (-5.52%) 428.47M
Most Actives (dollar volume)
Biogen Inc
287.77 -1.77 (-0.61%) 63.54B
Pfizer Inc.
31.70 +0.76 (2.46%) 190.82B
Johnson & Johnson
112.26 +1.27 (1.14%) 305.10B
Gilead Sciences, Inc.
72.70 +0.68 (0.94%) 94.78B
Bristol-Myers Squibb Co
57.04 +1.81 (3.28%) 95.31B